Evidence of intrapulmonary penetration of nacubactam, a novel β-lactamase inhibitor, following coadministration of nacubactam with meropenem in healthy adults
Abstract
Nacubactam is a novel non-β-lactam β-lactamase inhibitor being developed in combination with β-lactam antibiotics to treat serious gram-negative bacterial infections including nosocomial pneumonia. This study evaluated the systemic and intrapulmonary pharmacokinetics and safety of nacubactam plus meropenem in healthy adult male and female volunteers. Post-treatment bronchoalveolar lavage (BAL) to collect lung epithelial lining fluid (ELF). A total of 21 healthy adult participants were enrolled to receive a single dose of nacubactam 2 g coadministered with meropenem 2 g, of whom 20 underwent BAL and collection of blood samples for plasma pharmacokinetic (PK) characterization. The ratios of ELF to plasma area under the concentration-time curve from 0 to 8 h were 0.271 for nacubactam and 0.183 for meropenem. The estimated nacubactam half-life in ELF was 1.82 h and that in plasma was 1.71 h. PK data for meropenem were aligned with previously published results, with lower concentrations in ELF compared with plasma. The intrapulmonary penetration of nacubactam was favorable, with an area under the curve ratio (epithelial lining fluid to plasma) of 0.271, which was comparable to or greater than that observed for other approved β-lactamase inhibitors. The treatment combination was well tolerated, and no significant safety signals were identified. These data support further consideration of nacubactam/β-lactam combinations for the treatment of serious nosocomial pneumonia.CLINICAL…
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 21 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.